![AUROBAC THERAPEUTICS](https://aurobac-tx.com/wp-content/uploads/2023/09/aurobac-default.jpg)
John P. O’Donnell has joined the company as Chief Development Officer, in the newly formed subsidiary of AUROBAC THERAPEUTICS in the USA.
This strategic appointment reinforces the leadership team now established with Florence Séjourné as CEO, Martin Everett, Ph.D., as CSO, Johan Frieling, MD, Ph.D., as CMO, Julie Cervesi, Pharm.D., as Head of Business Development, Emeline Gardette, M.Sc., as Head of Chemistry, Manufacturing and Controls (CMC) and Frédérique Sablier-Gallis, Pharm.D., Ph.D., as Head of Project Management and Operations.